This page shows the latest Themis news and features for those working in and with pharma, biotech and healthcare.
Reduces CV events but falls down on increased bleeding risk. AstraZeneca unveiled the full data set from its phase 3 THEMIS trial at the ESC 2019, which investigated Brilinta in patients ... AZ had hopes to expand the label for Brilinta into this
Themis said in a statement however that the alliance is focused on “a vaccine that has the potential to provide a significant benefit to a great number of patients worldwide.”. ... The vaccine delivers the antigens directly to macrophages and
The results of the 19, 000-patient THEMIS trial will now form the basis of a regulatory filing later this year to expand the label for Brilinta (ticagrelor) for this ... We look forward to presenting the full results from the THEMIS trial later this year.
The product is being developed by Vienna-based vaccines specialist Themis, which has been working on this its lead product since it was founded in 2011. ... Themis’ vaccine candidate has shown a good safety and immune-response data in clinical testing
EUCLID's failure leaves AZ banking on the results of one final cardiovascular outcomes trial - the THEMIS study in patients with type 2 diabetes at high risk of cardiovascular events - to
The company is still waiting on the results of two other studies - the EUCLID trial in peripheral arterial disease (PAD) and THEMIS in patients with type 2 diabetes at high risk ... EUCLID should generate results later this year while THEMIS is due to
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...